Chlamydia is one of the most widespread sexually transmitted bacterial diseases in the world, causing an estimated 92 million infections globally per year. With existing treatment programs failing to stem the spread of infection, a vaccine is widely acknowledged as the only way to prevent the suffering and significant infertility caused by Chlamydia (C. trachomatis), the causative agent for the disease.
Recent advances in mass spectrometry technology, proteomics, genomics and Chlamydia immunology have resulted in significant advancements towards vaccine development. Through its Proof-of-Concept (POC) program Genome British Columbia (Genome BC) is funding the necessary pre-clinical studies to move a novel Chlamydia vaccine to human trials.
Genome British Columbia is a catalyst for the life sciences cluster on Canada's West Coast.
"Investment into public health is of significant importance to our province," says Dr. Alan Winter, President and CEO of Genome BC. "Genome BC remains committed to funding research that will result in practical, societal benefits and these projects demonstrate that."
Dr. Robert Brunham of the BC Centre for Disease Control is leading the POC project entitled "Accelerating the Development of a Novel Outer Membrane Protein Based Vaccine Against Chlamydia Infection". The project, in partnership with the Canadian not-for-profit Pan-Provincial Vaccine Enterprise Inc. (PREVENT), is expected to run over 21 months and will also include US Food and Drug Administration filings for anticipated clinical grade vaccine production.
The market profile for a Chlamydia vaccine is expected to be similar to the HPV vaccine currently on the market, which is now part of publicly funded healthcare and beginning to reduce HPV rates among Canadians.
Source: Marketwired News
Click here for the complete issue.